School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Department of Applied Biology and Chemical Technology, State Key Laboratory of Chirosciences, Hong Kong Polytechnic University, Hong Kong SAR, China.
Curr Med Chem. 2019;26(25):4799-4831. doi: 10.2174/0929867325666181001115225.
P-glycoprotein, also known as ABCB1 in the ABC transporter family, confers the simultaneous resistance of metastatic cancer cells towards various anticancer drugs with different targets and diverse chemical structures. The exploration of safe and specific inhibitors of this pump has always been the pursuit of scientists for the past four decades. Naturally occurring flavonoids as benzopyrone derivatives were recognized as a class of nontoxic inhibitors of P-gp. The recent advent of synthetic flavonoid dimer FD18, as a potent P-gp modulator in reversing multidrug resistance both in vitro and in vivo, specifically targeted the pseudodimeric structure of the drug transporter and represented a new generation of inhibitors with high transporter binding affinity and low toxicity. This review concerned the recent updates on the structure-activity relationships of flavonoids as P-gp inhibitors, the molecular mechanisms of their action and their ability to overcome P-gp-mediated MDR in preclinical studies. It had crucial implications on the discovery of new drug candidates that modulated the efflux of ABC transporters and also provided some clues for the future development in this promising area.
P-糖蛋白,又称 ABC 转运体家族中的 ABCB1,使转移性癌细胞对具有不同靶点和不同化学结构的各种抗癌药物同时产生耐药性。在过去的四十年中,科学家一直在探索这种泵的安全且特异性抑制剂。作为苯并吡喃衍生物的天然存在的类黄酮被认为是一类非毒性的 P-糖蛋白抑制剂。最近合成的类黄酮二聚体 FD18 的出现,作为一种有效的 P-糖蛋白调节剂,在体外和体内均能逆转多药耐药性,它特异性地针对药物转运体的拟二聚体结构,代表了具有高转运体结合亲和力和低毒性的新一代抑制剂。本综述涉及作为 P-糖蛋白抑制剂的类黄酮的结构-活性关系、作用机制以及在临床前研究中克服 P-糖蛋白介导的多药耐药性的能力的最新进展。这对发现调节 ABC 转运体外排的新药候选物具有重要意义,也为这一有前途的领域的未来发展提供了一些线索。